Literature DB >> 10030619

Telomeric length in individuals and cell lines with altered p53 status.

P A Kruk1, V A Bohr.   

Abstract

Telomeres play an important role in maintaining chromosomal stability and are often shortened in transformed cells. p53 is the most commonly mutated gene in cancers and its status is thought to reflect the level of genomic stability. We measured telomeric length by Southern blot analysis in cells from cancer-prone syndromes and in selected cancer cells with altered p53 status. Mean telomeric lengths in the cancer-prone syndromes Li-Fraumeni syndrome, Fanconi's anemia, and ataxia telangiectasia, were shorter in the affected individuals than in their unaffected parents. We also found that altered p53 expression in selected cancer cell model systems may be associated with shortened telomeric length, but did not appear to be associated with significant alterations in telomerase activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10030619     DOI: 10.1002/(SICI)1520-6823(1999)7:1<13::AID-ROI2>3.0.CO;2-7

Source DB:  PubMed          Journal:  Radiat Oncol Investig        ISSN: 1065-7541


  4 in total

1.  TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset.

Authors:  Carla Pinto; Isabel Veiga; Manuela Pinheiro; Ana Peixoto; Armando Pinto; José M Lopes; Rui M Reis; Carla Oliveira; Manuela Baptista; Lúcia Roque; Fernando Regateiro; Luís Cirnes; Robert M W Hofstra; Raquel Seruca; Sérgio Castedo; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2009-05-26       Impact factor: 2.375

2.  Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche.

Authors:  Pan Pantziarka
Journal:  Ecancermedicalscience       Date:  2015-05-21

Review 3.  Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.

Authors:  Pan Pantziarka; Sarah Blagden
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

4.  Li Fraumeni syndrome, cancer and senescence: a new hypothesis.

Authors:  Pan Pantziarka
Journal:  Cancer Cell Int       Date:  2013-04-15       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.